Web• Tecartus suspension for intravenous infusion; 1 infusion bag (~68 mL): 71287-0219-xx VII. References 1. Tecartus [package insert]. Santa Monica, CA; Kite Pharma, Inc., July 2024. Accessed October 2024. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) brexucabtagene autoleucel. WebSep 1, 2024 · Tecartus Prescribing Information Package insert / product label Generic name: brexucabtagene autoleucel Dosage form: intravenous suspension Drug class: …
Tecartus (Brexucabtagene Autoleucel Suspension): Uses, …
WebSelect patients for therapy based on an FDA-approved companion diagnostic test [see Dosage and Administration (2.1)]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or WebTECARTUS ® is the first and only FDA-approved CAR T-cell therapy for adults (18+ years) living with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) 1-3 CAR T-cell therapy uses the target specificity of antibody therapy to direct the cytotoxic immune response 4 eia refinery margin
Frequently Asked Questions About Tecartus ... - CancerConnect
Web7 DRUG INTERACTIONS . 7.1 . Effects of Other Drugs on TUKYSA 7.2 . Effects of TUKYSA on Other Drugs . 8 USE IN SPECIFIC POPULATIONS . 8.1 Pregnancy . 8.2 Lactation . 8.3 Females and Males of Reproductive Potential . 8.4 Pediatric Use . 8.5 Geriatric Use . 8.6 Renal Impairment . 8.7 Hepatic Impairment . 11 DESCRIPTION 12 CLINICAL … WebTECARTUS ® is the first FDA-approved CAR T-cell therapy for adults (18+ years) living with relapsed or refractory B-cell precursor acute lymphoblastic leukemia1-3 FDA APPROVED WITH BREAKTHROUGH THERAPY DESIGNATION 4 OVERALL COMPLETE REMISSION 1 65% CR/CRi (n=35/54) DEEP 1 52 % CR (n=28/54) DURABLE 1 13.6 M O N T H S … WebOct 4, 2024 · Tecartus is an autologous, anti-CD19 CAR T-cell therapy. It is made from the patient's own white blood cells which have been modified to recognize and attack the lymphoma cells. Tecartus is administered via intravenous infusion. The Tecartus product label carries a boxed warning for cytokine release syndrome and neurologic toxicities. follower equipment bfa